PLx Pharma

Quick facts

Marketed products

• Aspirin tablets · Cardiovascular; Pain management; Inflammation
  Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects.
• PL-ASA · Cardiovascular
  PL-ASA is a combination formulation of aspirin with a protective coating designed to reduce gastrointestinal irritation and bleeding risk while maintaining antiplatelet efficacy.

Phase 3 pipeline

• Enteric-coated aspirin caplets · Cardiovascular
  Aspirin inhibits platelet aggregation by irreversibly acetylating cyclooxygenase (COX) enzymes, reducing thromboxane A2 production and preventing clot formation.
• Immediate-Release Aspirin Tablets · Cardiovascular
  Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.
• PL2200 Aspirin Capsules · Cardiovascular
  PL2200 is a modified-release aspirin formulation designed to reduce gastrointestinal irritation while maintaining antiplatelet efficacy.

Phase 2 pipeline

• Ibuprofen-PC
• PL2200
• PL3100

Phase 1 pipeline

• PL 3100
• PL2200 fasted
• PL2200 fed

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• PLx Pharma portfolio CI brief
• PLx Pharma pipeline updates RSS